Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 2/20 | 0.45 |
| ▸ | IKBKB | O14920 | 16/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 4/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | PRKACG | P22612 | 1/20 | 0.39 |
| ▸ | PRKACB | P22694 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2134413 | 0.86 | BRAF (0.44) | BRAFIKBKBLIMK1CHUKPRKACA | |
| SCHEMBL2131263 | 0.84 | BRAF (0.45) | BRAFIKBKBLIMK1CHUKPRKACA | |
| SCHEMBL2131284 | 0.83 | BRAF (0.56) | BRAFIKBKBLIMK1PDE4APDE4B | |
| SCHEMBL2134347 | 0.82 | LIMK1 (0.47) | BRAFIKBKBLIMK1CHUKPRKACA | |
| SCHEMBL2133783 | 0.82 | BRAF (0.40) | BRAFIKBKBCDK8CDK19 | |
| SCHEMBL2130627 | 0.81 | IKBKB (0.49) | BRAFIKBKBLIMK1CHUKPRKACA | |
| SCHEMBL2133506 | 0.77 | IKBKB (0.54) | BRAFIKBKBLIMK1CHUKPRKACA | |
| SCHEMBL1176204 | 0.77 | BRAF (0.55) | BRAFIKBKBLIMK1CHUKPRKACA | |
| SCHEMBL2134604 | 0.76 | BRAF (0.45) | BRAFIKBKBLIMK1CHUKPRKACA | |
| SCHEMBL2132343 | 0.74 | IKBKB (0.50) | IKBKBLIMK1CHUKPRKACAPRKACG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445916-A1 | ALKOXY-THIENOPYRIMIDINES AS TGF-BETA RECEPTOR KINASE MODULATORS | Merck Patent GmbH (DE) | 2012-05-02 | — | — | EP | claimed |
| US-20120101095-A1 | ALKOXY-THIENOPYRIMIDINES AS TGF-BETA RECEPTOR KINASE MODULATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-04-26 | — | — | US | claimed |
| WO-2010149257-A1 | ALKOXY-THIENOPYRIMIDINES AS TGF-BETA RECEPTOR KINASE MODULATORS | MERCK PATENT GMBH (DE) | 2010-12-29 | — | — | WO | claimed |
| US-20120101095-A1 | ALKOXY-THIENOPYRIMIDINES AS TGF-BETA RECEPTOR KINASE MODULATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101095-A1 | ALKOXY-THIENOPYRIMIDINES AS TGF-BETA RECEPTOR KINASE MODULATORS | TGFBR1, TGFBR2, TGFB1 | BRAF 153/4885IKBKB 100/4885LIMK1 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.